Xiao Xiao-Guang, Wang Shu-Jing, Hu Li-Ya, Chu Qian, Wei Yao, Li Yang, Mei Qi, Chen Yuan
Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China E-mail :
Asian Pac J Cancer Prev. 2014;15(15):6415-9. doi: 10.7314/apjcp.2014.15.15.6415.
To explore the relationship between SER (time between the start of any treatment and the end of radiation therapy) and the survival of patients with limited-stage small cell lung cancer.
Between 2008 and 2013, 135 cases of limited-stage small cell lung cancer (LS-SCLC) treated with consecutively curative chemoradiotherapy were included in this retrospective analysis. In terms of SER, patients were divided into early radiotherapy group (SER<30 days, n=76) and late radiotherapy group (SER≥30 days, n=59) with a cut- off of SER 30 days. Outcomes of the two groups were compared for overall survival.
For all analyzable patients, median follow-up time was 23.8 months and median overall survival time was 16.8 months. Although there was no significant differences in distant metastasis free survival between the two groups, patients in early radiotherapy group had a significantly better PFS (p=0.003) and OS (p=0.000).
A short SER may be a good prognostic factor for LD-SCLC patients treated with concurrent chemoradiotherapy.
探讨开始任何治疗至放射治疗结束的时间间隔（SER）与局限期小细胞肺癌患者生存率之间的关系。
2008年至2013年期间，135例接受了连续根治性放化疗的局限期小细胞肺癌（LS-SCLC）患者纳入本回顾性分析。根据SER，将患者分为早期放疗组（SER<30天，n=76）和晚期放疗组（SER≥30天，n=59），SER的截断值为30天。比较两组的总生存结局。
对于所有可分析的患者，中位随访时间为23.8个月，中位总生存时间为16.8个月。虽然两组之间的无远处转移生存期无显著差异，但早期放疗组患者的无进展生存期（PFS，p=0.003）和总生存期（OS，p=0.000）显著更好。
较短的SER可能是同步放化疗治疗的局限期小细胞肺癌患者的良好预后因素。
